Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Transcription factors.

M L Handel1, L Girgis

  • 1Garvan Institute of Medical Research & University of New South Wales, 384 Victoria Street, Darlinghurst, NSW, 2010, Australia.

Best Practice & Research. Clinical Rheumatology
|January 29, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Potential role of coenzyme Q10 in facilitating recovery from statin-induced rhabdomyolysis.

Internal medicine journal·2015
Same author

Targeting adenosine receptors in the treatment of allergic rhinitis: a randomized, double-blind, placebo-controlled study.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2007
Same author

Synovial fluid induced nuclear factor-kappaB DNA binding in a monocytic cell line.

The Journal of rheumatology·2000
Same author

Rheumatic manifestations of hyperlipidaemia.

Bailliere's best practice & research. Clinical rheumatology·2000
Same author

Inhibition of transcription factors by anti-inflammatory and anti-rheumatic drugs: can variability in response be overcome?

Clinical and experimental pharmacology & physiology·2000
Same author

Carboxyfluorescein diacetate succinimidyl ester and the virgin lymphocyte: a marriage made in heaven.

Immunology and cell biology·1999
Same journal

The young adult with Juvenile Idiopathic Arthritis (JIA): A clinical review of transition, complications, and psychosocial management.

Best practice & research. Clinical rheumatology·2026
Same journal

Impact of fatigue on rheumatic diseases: Current perspectives.

Best practice & research. Clinical rheumatology·2026
Same journal

Pneumocystis prophylaxis in rheumatic disease.

Best practice & research. Clinical rheumatology·2026
Same journal

Cutaneous manifestations in myositis syndromes.

Best practice & research. Clinical rheumatology·2026
Same journal

Systemic sclerosis: A comprehensive systematic review of global epidemiology, sex and ethnic disparities, disease burden, and organ-specific involvement.

Best practice & research. Clinical rheumatology·2026
Same journal

Alopecia across the spectrum of rheumatic disease.

Best practice & research. Clinical rheumatology·2026
See all related articles

Transcription factors regulate gene expression and cell phenotype. Targeting specific transcription factors, like NF-kappaB, may offer safer and more effective treatments for rheumatic diseases.

Area of Science:

  • Molecular Biology
  • Immunology
  • Rheumatology

Background:

  • Gene expression regulation by transcription factors is crucial for cell phenotype.
  • Inflammatory processes involve induced gene expression, contributing to rheumatic diseases.
  • Key transcription factors like NF-kappaB, AP-1, NFATs, and STATs drive inflammatory gene expression.

Purpose of the Study:

  • To review the role of transcription factors in rheumatic disease pathogenesis.
  • To discuss current therapeutic strategies targeting transcription factors.
  • To explore the potential of novel transcription factor-specific drugs.

Main Methods:

  • Literature review of transcription factor function in inflammation and rheumatic diseases.
  • Analysis of existing anti-rheumatic and anti-inflammatory drug mechanisms.

Related Experiment Videos

  • Discussion of future therapeutic development targeting transcription factors.

    • Main Results:

    • Specific transcription factors (NF-kappaB, AP-1, NFATs, STATs) are central to inflammatory gene expression in rheumatic diseases.
    • Current drugs can modify these transcription factors, but efficacy and side effects are limitations.
    • Targeting transcription factors, particularly NF-kappaB, shows therapeutic promise.

    Conclusions:

    • Transcription factors are critical mediators in the pathogenesis of rheumatic diseases.
    • Developing drugs that specifically target transcription factors could improve treatment safety and efficacy.
    • NF-kappaB is a key target for future anti-rheumatic drug development.